Agenus (NASDAQ:AGEN) Receives “Buy” Rating from HC Wainwright

Agenus (NASDAQ:AGEN)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $23.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 385.23% from the company’s previous close.

Several other research analysts have also weighed in on AGEN. Zacks Research raised Agenus to a “hold” rating in a research report on Tuesday, August 12th. Wall Street Zen cut Agenus from a “buy” rating to a “hold” rating in a research note on Sunday, August 17th. Finally, Robert W. Baird raised their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research report on Wednesday, June 4th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $14.50.

Agenus Stock Performance

NASDAQ AGEN opened at $4.74 on Wednesday. The firm’s 50 day moving average price is $5.17 and its two-hundred day moving average price is $3.83. Agenus has a twelve month low of $1.38 and a twelve month high of $7.34. The stock has a market cap of $151.04 million, a price-to-earnings ratio of -0.66 and a beta of 1.44.

Agenus (NASDAQ:AGEN) last released its earnings results on Monday, August 11th. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.22). The business had revenue of $25.70 million during the quarter, compared to the consensus estimate of $49.71 million. On average, research analysts forecast that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Barclays PLC raised its position in shares of Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 4,924 shares during the period. Apollon Wealth Management LLC grew its stake in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 5,000 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in Agenus in the 2nd quarter valued at $50,000. Jump Financial LLC bought a new position in Agenus in the 2nd quarter worth $55,000. Finally, CWM LLC lifted its position in Agenus by 105.8% during the 2nd quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 13,494 shares during the last quarter. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.